Skip to main content
Article
Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin
Blood (1999)
  • Langdon L. Miller, Pfizer
  • Edward L. Korn, National Institutes of Health
  • Diane S. Stevens, Science Applications International Corporation
  • John E. Janik, National Institutes of Health
  • Barry L. Gause, National Institutes of Health
  • William C. Kopp, National Institutes of Health
  • Jon T. Holmlund, National Institutes of Health
  • Brendan D. Curti, National Institutes of Health
  • Mario Sznol, Vion Pharmaceuticals, Inc.
  • John W. Smith, University of Michigan
  • Walter J. Urba, Providence Portland Medical Center
  • Sarah E. Donegan, Memorial Hospital of South Bend
  • Thelma M. Watson, National Institutes of Health
  • Dan L. Longo, National Institutes of Health
Publication Date
May 15, 1999
Citation Information
Langdon L. Miller, Edward L. Korn, Diane S. Stevens, John E. Janik, et al.. "Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin" Blood Vol. 93 Iss. 10 (1999) p. 3250 - 3258
Available at: http://works.bepress.com/walter-urba/238/